Abstract:Gene-based virotherapy mediated by oncolytic viruses is currently experiencing a renaissance in cancer therapy. However, relatively little attention has been given to the potentiality of dual gene virotherapy strategy as a novel therapeutic approach to mediate triplex anticancer combination effects, particularly if the two suitable genes are well chosen. Both tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and interleukin-12 (IL-12) have been emerged as promising pharmacological candidates in cancer therapy; however, the combined efficacy of TRAIL and IL-12 genes for treatment of human hepatocellular carcinoma (HCC) remains to be determined.Herein, we investigated the therapeutic efficacy of concurrent therapy with two armed oncolytic adenoviruses encoding human TRAIL gene (Ad-ΔB/TRAIL) and IL-12 gene (Ad-ΔB/IL-12), respectively, on preclinical models of human HCC, and also elucidated the possible underlying mechanisms. The effects of Ad-ΔB/TRAIL+Ad-ΔB/IL-12 combination therapy were assessed both in vitro on Hep3B and HuH7 human HCC cell lines and in vivo on HCC-orthotopic model established in the livers of athymic nude mice by intrahepatic implantation of human Hep3B cells.Compared to therapy with non-armed control Ad-ΔB, combined therapy with Ad-ΔB/TRAIL+Ad-ΔB/IL-12 elicited profound anti-HCC killing effects on Hep3B and HuH7 cells and on the transplanted Hep3B-orthotopic model. Efficient viral replication and TRAIL and IL-12 expression were also confirmed in HCC cells and the harvested tumor tissues treated with this combination therapy. Mechanistically, co-therapy with Ad-ΔB/TRAIL+Ad-ΔB/IL-12 exhibited an enhanced effect on apoptosis promotion, activation of caspase-3 and-8, generation of anti-tumor immune response evidenced by upregulation of interferon gamma (IFN-γ) production and infiltration of natural killer-and antigen presenting cells, and remarkable repression of intratumor vascular endothelial growth factor (VEGF) and cluster of differentiation 31 (CD31) expression and tumor microvessel density.Overall, our data showed a favorable therapeutic effect of Ad-ΔB/TRAIL+Ad-ΔB/IL-12 combination therapy against human HCC, and may therefore constitute a promising and effective therapeutic strategy for treating human HCC. However, further studies are warranted for its reliable clinical translation.

Fiber-modified Adenoviral Vector Expressing the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene from the Human Telomerase Reverse Transcriptase Promoter Induces Apoptosis in Human Hepatocellular Carcinoma Cells

Targeted Expression of Green Fluorescent Protein/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein from Human Telomerase Reverse Transcriptase Promoter Elicits Antitumor Activity Without Toxic Effects on Primary Human Hepatocytes

Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29.

Anti-liver Cancer Activity of TNF-related Apoptosis-Inducing Ligand Gene and Its Bystander Effects.

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.

[Activity of the TNF-related Apoptosis-Inducing Ligand Gene Expressed from the Htert Promoter on Colon Cancer Cell Line HT-29].

Gene therapy in colon cancer cells with a fiber-modified adenovector expressing the TRAIL gene driven by the hTERT promoter.

Conditionally Replicative Adenovirus Vector Carrying Trail Gene For Enhanced Oncolysis Of Human Hepatocellular Carcinoma

A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma

Suppressing Orthotopic Pancreatic Tumor Growth With A Fiber-Modified Adenovector Expressing The Trail Gene From The Human Telomerase Reverse Transcriptase Promoter

Potent Antitumor Effect of Trail Mediated by A Novel Adeno-Associated Viral Vector Targeting to Telomerase Activity for Human Hepatocellular Carcinoma

AAV-mediated TRAIL Gene Expression Driven by Htert Promoter Suppressed Human Hepatocellular Carcinoma Growth in Mice

Adenovirus-Mediated Combined Anti-Angiogenic and Pro-Apoptotic Gene Therapy Enhances Antitumor Efficacy in Hepatocellular Carcinoma

Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter

[Action of Apoptosis-Induced Ligand Gene in Relation to Tumor Necrosis Factor on Human Colon Cancer Cell Line HT29].

Construction of Recombinant Adenovirus Containing Soluble Tumor Necrosis Factor-related Apoptosis-inducing Ligand Gene and its Expression in Liver Cancer Cell Line

Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell.

Combined Therapy with Oncolytic Adenoviruses Encoding TRAIL and IL-12 Genes Markedly Suppressed Human Hepatocellular Carcinoma Both in Vitro and in an Orthotopic Transplanted Mouse Model

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3